The litigation was initiated by Astellas Pharma against Zydus Lifesciences concerning the validity of the ‘780 patent’, which covers a sustained release formulation of ‘mirabegron’. The court’s decision marks a preliminary win for Astellas in the ongoing dispute.
While the court has ruled on the validity of the ‘780 patent’, the matter is far from resolved. Further litigation concerning the infringement of the ‘780 patent, potential damages, and any additional invalidity theories will be consolidated into a jury trial scheduled for 2026. The outcome of this trial could have significant implications for Zydus Lifesciences’ future operations related to mirabegron products in the US market.
Zydus Lifesciences, in its regulatory filing, stated that there are no immediate material financial implications as of the date of the court order. However, the company is currently evaluating the potential impact of the ruling on its operations and is exploring available legal remedies. It is still determining the full extent of the consequences of this decision and preparing for the upcoming jury trial. Zydus Lifesciences has assured stakeholders that it will provide further updates as the situation develops. The company remains committed to defending its position and exploring all available options to mitigate any potential adverse effects of the litigation.
